Resources/Benzoyl Peroxide Concentration Limits: Cosmetic vs. OTC Drug Status
Benzoyl Peroxide Concentration Limits: Cosmetic vs. OTC Drug Status
Disclaimer: The information provided in this guide is for educational and regulatory context purposes only and does not constitute formal legal advice. Compliance requirements can vary based on formulation, regional authority updates, and specific product claims. Consult a certified regulatory affairs professional or specialized legal counsel for official filings.
Benzoyl Peroxide (BPO) is a substance with distinct regulatory classifications depending on its intended use and concentration, primarily oscillating between a cosmetic ingredient and an Over-the-Counter (OTC) drug active. This dual status significantly impacts permissible concentration limits and market access across different jurisdictions.
United States (FDA): OTC Drug Monograph Status
In the United States, Benzoyl Peroxide is primarily regulated as an active pharmaceutical ingredient (API) under the FDA's OTC Drug Monograph for acne treatment. Products containing BPO for acne treatment are therefore classified as drugs, not cosmetics, and must comply with drug manufacturing (cGMP) and labeling requirements. Cosmetic products are generally not permitted to make drug claims or contain drug-level active ingredients.
- Intended use and product claims (e.g., "treats acne") dictate drug classification.
- Specific concentration ranges for OTC drug products are defined within the FDA's OTC Drug Monograph for acne.
- Manufacturing facilities must adhere to drug current Good Manufacturing Practices (cGMP).
European Union (EC No 1223/2009): Prohibited in Cosmetics
Under the EU Cosmetics Regulation (EC) No 1223/2009, Benzoyl Peroxide is generally prohibited for use in cosmetic products. It is listed in Annex II of the Regulation, which enumerates substances that cosmetic products must not contain. Its primary application in the EU is within medicinal products, requiring a marketing authorization as a drug, not as a cosmetic ingredient.
- Benzoyl Peroxide is included in EU Annex II (Prohibited Substances) for cosmetic products.
- Any product containing BPO with a therapeutic effect would be classified as a medicinal product.
- There is no recognized cosmetic function for Benzoyl Peroxide under the EU Cosmetics Regulation.
Other Jurisdictions: Varied Classifications
Other global markets exhibit varied approaches to Benzoyl Peroxide. For instance, Health Canada's Cosmetic Ingredient Hotlist may list restrictions or prohibitions, while the UK, post-Brexit, largely mirrors EU regulations but maintains its own enforcement body (OPSS). ASEAN member states, guided by the ASEAN Cosmetic Directive (ACD), also have specific lists of prohibited or restricted substances. Some regions might permit BPO in cosmetics at very low, non-therapeutic concentrations, or classify it as a quasi-drug, depending on local regulatory frameworks and interpretations of cosmetic versus therapeutic function.
- Specific national cosmetic regulations or positive/negative lists dictate permissible use.
- Classification as a drug, quasi-drug, or cosmetic ingredient is often based on concentration and claims.
- Local interpretations of "cosmetic purpose" versus "therapeutic effect" are critical.
Given the critical distinction between cosmetic and drug classifications, formulators and regulatory professionals must verify the precise status and permissible concentration limits for Benzoyl Peroxide in each target market. The Molecule Lab's compliance engine provides up-to-date regulatory data. To confirm current limits and classifications:
- Search for "Benzoyl Peroxide" in the public-search or your workspace.
- Specify the target market (e.g., US, EU, Canada, UK).
- Review the classification (cosmetic, OTC drug, prohibited) and associated concentration limits or conditions of use.
- Consult the relevant regulatory annexes or monographs linked within the platform for full details.
This content was generated by AI. Always verify the information before use.